Asosiy kontentga oʻtish
AkademIndex

Xizmatlar

Maqola

USP11 deubiquitinates GATA3 to suppress the growth and metastasis of luminal-type breast cancers

Qian TaoGuangdong Provincial Key Laboratory of Infection Immunity and Inflammation, International Cancer Center, Marshall Laboratory of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University General Hospital, Shenzhen, Guangdong, 518060, China. Electronic address: [email protected]Xiong LiuGuangdong Provincial Key Laboratory of Infection Immunity and Inflammation, International Cancer Center, Marshall Laboratory of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University General Hospital, Shenzhen, Guangdong, 518060, ChinaFeng BaiGuangdong Provincial Key Laboratory of Infection Immunity and Inflammation, International Cancer Center, Marshall Laboratory of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University General Hospital, Shenzhen, Guangdong, 518060, China; Department of Pathology, Shenzhen University Medical School, Shenzhen, Guangdong, 518060, ChinaQiyue HeGuangdong Provincial Key Laboratory of Infection Immunity and Inflammation, International Cancer Center, Marshall Laboratory of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University General Hospital, Shenzhen, Guangdong, 518060, ChinaYipei XuGuangdong Provincial Key Laboratory of Infection Immunity and Inflammation, International Cancer Center, Marshall Laboratory of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University General Hospital, Shenzhen, Guangdong, 518060, ChinaJiayi ZhangGuangdong Provincial Key Laboratory of Infection Immunity and Inflammation, International Cancer Center, Marshall Laboratory of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University General Hospital, Shenzhen, Guangdong, 518060, ChinaShiwen ZhangGuangdong Provincial Key Laboratory of Infection Immunity and Inflammation, International Cancer Center, Marshall Laboratory of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University General Hospital, Shenzhen, Guangdong, 518060, ChinaShaoling YeGuangdong Provincial Key Laboratory of Infection Immunity and Inflammation, International Cancer Center, Marshall Laboratory of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University General Hospital, Shenzhen, Guangdong, 518060, ChinaYuchan WangGansu Dian Medical Laboratory, Lanzhou, 730000, ChinaBin PengGuangdong Key Laboratory for Genome Stability & Disease Prevention and International Cancer Center, Shenzhen University Medical School, Shenzhen, Guangdong, 518060, China; Shenzhen-Almaty Joint Laboratory for Frontiers in Medical Science (salFMS), Shenzhen University Medical School, Shenzhen, Guangdong, 518060, ChinaKapanova GulnaraShenzhen-Almaty Joint Laboratory for Frontiers in Medical Science (salFMS), Shenzhen University Medical School, Shenzhen, Guangdong, 518060, China; Department of Health Policy and Organization, Al-Farabi Kazakh National University, Almaty, 050040, KazakhstanJasur RizaevSamarkand State Medical InstituteWei‐Guo ZhuDepartment of Biochemistry and Molecular Biology, International Cancer Center, Shenzhen University Medical School, Shenzhen, Guangdong, 518060, ChinaXingzhi XuGuangdong Key Laboratory for Genome Stability & Disease Prevention and International Cancer Center, Shenzhen University Medical School, Shenzhen, Guangdong, 518060, China; Shenzhen-Almaty Joint Laboratory for Frontiers in Medical Science (salFMS), Shenzhen University Medical School, Shenzhen, Guangdong, 518060, China. Electronic address: [email protected]Xin‐Hai PeiGuangdong Provincial Key Laboratory of Infection Immunity and Inflammation, International Cancer Center, Marshall Laboratory of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University General Hospital, Shenzhen, Guangdong, 518060, China; Department of Anatomy and Histology, Shenzhen University Medical School, Shenzhen, Guangdong, 518060, China. Electronic address: [email protected]
2026en
Ochiq kirishOltin

Litsenziya: cc-by

ABI

Annotatsiya

Luminal breast cancers account for 70%-80% of total breast cancer cases. More than half of luminal breast cancers either relapse after treatment or lose their luminal features, resulting in poorly differentiated cancers with enhanced invasiveness and metastasis, yet the mechanisms remain largely elusive. In this study, we demonstrated that USP11 suppresses the proliferation and migration of luminal epithelial and tumor cells in vitro, but not basal-like tumor cells. Consistently, USP11 inhibits luminal tumorigenesis and metastasis, but promotes basal-like tumorigenesis in vivo. Mechanistically, USP11 positively regulates GATA3, p27, and ERα in a deubiquitinase activity-dependent manner. USP11 deubiquitinates GATA3, which subsequently binds to and transcriptionally activates CDKN1B (encoding p27). USP11 stimulates CDKN1B and ESR1 (encoding ERα) transcription in a GATA3-dependent manner. GATA3 knockdown reverses the increase in p27 and ERα and the decrease in cell proliferation and migration induced by USP11 overexpression, and p27 knockdown rescues the proliferative inhibition induced by USP11 or GATA3 overexpression in luminal tumorigenesis. USP11 overexpression sensitizes luminal breast cancer cells to tamoxifen treatment. The expression levels of USP11, GATA3, p27, and ERα are positively correlated with each other in human breast tumors and cell lines. We thus identify a novel USP11-GATA3 axis that governs luminal cell fate and restrains luminal cell proliferation and migration during mammary tumor development and metastasis.

Hali tarjima qilinmagan

Identifikatorlar

DOI
10.1016/j.jbc.2026.113371

Iqtiboslar va manbalar

0 ta iqtibos67 ta foydalanilgan manba